A clinical-stage biotechnology company in Immuno-Oncology and Immuno-Inflammation

Focused on developing and partnering therapies to control the immune system for Immuno-Oncology and Immuno-Inflammation.

Corporate presentation

Appendix to press release issued 5 May 2025: CoTikiS Study backgrounder

Our latest press release

23/05/2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

Download

First-in-class clinical assets in immuno-oncology and immuno-inflammation combined with proprietary research platforms

Immuno-Oncology

Immuno-Inflammation

Preclinical platforms

T-cell activation through neo-epitopes
Transforming tumor microenvironment
suppressive cells into effector cells

Down regulating T effector cells to decrease immunological reactivity

Up regulating regulatory
T-cells to develop immune tolerance

Three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies

Immuno-Oncology

T-cell activation through neo-epitopes
Transforming tumor microenvironment
suppressive cells into effector cells

Immuno-Inflammation

Down regulating T effector cells to decrease immunological reactivity

Up regulating regulatory
T-cells to develop immune tolerance

Preclinical platforms

Three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies

Partnerships

Premier international pharma, clinical and academic collaborations to speed up the delivery of our product candidates to patients in need

Investors

To download the documents